- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.01. | Aclarion raises $10.4 million to fund chronic back pain technology | 3 | Investing.com | ||
| ACLARION Aktie jetzt für 0€ handeln | |||||
| 13.01. | Aclarion schließt Finanzierung über 10,4 Millionen US-Dollar für Technologie gegen Rückenschmerzen ab | 7 | Investing.com Deutsch | ||
| 13.01. | Aclarion, Inc.: Aclarion Strengthens Balance Sheet and Extends Cash Runway Into 2028 | 380 | GlobeNewswire (Europe) | BROOMFIELD, Colo., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers... ► Artikel lesen | |
| 09.01. | Aclarion, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 08.01. | Aclarion Stock Climbs 50% After Strong 2025 Results And 2026 Outlook | 9 | RTTNews | ||
| 08.01. | Aclarion-Aktie steigt sprunghaft an: Scan-Volumen von Nociscan im 4. Quartal um 114 % gewachsen | 11 | Investing.com Deutsch | ||
| 08.01. | Aclarion's AI Back Pain Tech Sees 114% Surge In Demand, Stock Soars | 9 | Benzinga.com | ||
| 08.01. | Aclarion to enroll around 25% of patients in CLARITY trial by Q2 | 3 | Seeking Alpha | ||
| 08.01. | Aclarion, Inc.: Aclarion Provides 2025 Update and 2026 Corporate Outlook | 163 | GlobeNewswire (Europe) | Quarterly Nociscan scan volumes increased 114% year-over-year in Q4 2025Annual Nociscan scan volumes increased 69% year-over-year in 2025Debt-free balance sheet with $12.0 million in cash as of December... ► Artikel lesen | |
| 06.01. | Aclarion, Inc.: Aclarion Announces First Patient Enrollments at Two Additional CLARITY Trial Sites and Provides Guidance on Expected Availability of Initial Data | 79 | GlobeNewswire (Europe) | Northwestern and Scripps Health join two previously announced sites in achieving this critical patient enrollment milestone Seven leading U.S. spine centers have now completed the regulatory and operational... ► Artikel lesen | |
| 04.12.25 | Aclarion-Aktie steigt nach Vorstellung von Wirbelsäulen-Technologie in Fachjournal | 4 | Investing.com Deutsch | ||
| 04.12.25 | Aclarion's Nociscan featured in special pain issue of spine journal | 1 | Investing.com | ||
| 04.12.25 | Aclarion, Inc.: Aclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS) | 1 | GlobeNewswire (USA) | ||
| 12.11.25 | Aclarion: Interview With CEO Brent Ness About The Digital Health Company Addressing A Worldwide Epidemic | 4 | pulse2.com | ||
| 12.11.25 | Aclarion, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 05.11.25 | Aclarion appoints first UK commercial director as insurance coverage expands | 1 | Investing.com | ||
| 05.11.25 | Aclarion, Inc.: Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion | 2 | GlobeNewswire (USA) | ||
| 22.10.25 | Aclarion, Inc.: Aclarion Wins "Rising Star" at 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH | 11 | GlobeNewswire (USA) | ||
| 14.10.25 | Aclarion reports 89% increase in Nociscan scan volumes in Q3 | 1 | Investing.com | ||
| 14.10.25 | Aclarion, Inc.: Aclarion Provides Corporate Update Highlighting Market Expansion as CLARITY Trial Advances Toward Key Data Catalyst | 212 | GlobeNewswire (Europe) | Debt-free balance sheet with $13.3 million in cash as of today ($15.11 per share fully diluted) providing strategic flexibility for continued commercial growth Nociscan scan volumes increase +89%... ► Artikel lesen |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| UNITEDHEALTH | 296,15 | +0,03 % | UnitedHealth vor Zahlen: Darauf kommt es an | Die Berichtssaison in den USA nimmt peu à peu Fahrt auf. Am morgigen Dienstag wird der größte US-Krankenversicherer UnitedHealth vor US-Börseneröffnung die Zahlen für das vergangene vierte Quartal respektive... ► Artikel lesen | |
| INTUITIVE SURGICAL | 447,40 | +0,52 % | Intuitive Surgical: Prognosen vom OP-Tisch gefegt | Einmal mehr hat die US-Gesellschaft Intuitive Surgical ein bärenstarkes Quartal abgeliefert. Der Spezialist im Bereich der Roboter-assistierten Chirurgie konnte die Markterwartungen an das Schlussviertel... ► Artikel lesen | |
| THERMO FISHER | 531,70 | +0,80 % | Schlägt Thermo Fisher zu?: Qiagen: Übernahmegerüchte schicken die Aktie auf Kursachterbahn | © Foto: Rafael Henrique - picture allianceÜbernahmegerüchte um den Diagnostikspezialisten Qiagen sorgten am Dienstag für einen rekordverdächtigen Kursanstieg. Am Mittwoch kommt die Aktie wieder etwas... ► Artikel lesen | |
| ROKU | 90,02 | -0,03 % | How I turned my cheap Roku TV into a piece of art (like the $3,000 Samsung Frame TV) | ||
| ATOSSA THERAPEUTICS | 0,582 | +1,39 % | ATOSSA THERAPEUTICS, INC. - 8-K, Current Report | ||
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update | -- Increased Net Sales 10% While Lowering Operating Expenses 42% vs. Prior Year Quarter --
-- Delivered $1.0 Million of Operating Income in Q3 2025 --
SAN DIEGO... ► Artikel lesen | |
| CENTENE | 38,745 | -0,49 % | Centene Expands Palliative Care Access in Ohio Through Tuesday Health | ||
| QUIDELORTHO | 24,200 | 0,00 % | QuidelOrtho: UBS hebt Kursziel wegen starker Saison für Atemwegserkrankungen auf 35 Dollar an | ||
| VERU | 2,630 | -6,07 % | Veru Inc.: Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress | -- Following positive efficacy and safety results from Phase 2b QUALITY study, company received FDA regulatory clarity for enobosarm in combination with GLP-1 RA -- -- Incremental weight loss is an... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 6,010 | -100,00 % | Upgrade von H.C. Wainwright beflügelt Aktie von Tempest Therapeutics | ||
| NANO-X IMAGING | 3,010 | 0,00 % | NANO-X IMAGING LTD: Nanox Engages with Althea France to Accelerate European Commercialization of Nanox.ARC System | Althea France, part of one of Europe's largest independent medical technology services providers, to distribute CE-marked Nanox.ARC system across French healthcare sector Partnership represents Nanox's... ► Artikel lesen | |
| FULGENT GENETICS | 23,400 | +0,86 % | FLGT to Acquire Bako & StrataDx Assets to Expand Pathology Platform | ||
| LANTHEUS | 57,36 | +0,49 % | Lantheus Holdings, Inc.: Lantheus Announces Closing of SPECT Business Sale to SHINE Technologies | BEDFORD, Mass., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians... ► Artikel lesen | |
| PERSPECTIVE THERAPEUTICS | 2,300 | +5,50 % | Perspective Therapeutics, Inc.: Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results | Updated interim results from the Company's [212Pb]VMT-a-NET Phase 1/2a study supporting the therapy's compelling overall clinical profile at the 5 mCi dose were presented at the ESMO Congress 2025... ► Artikel lesen | |
| AMN HEALTHCARE SERVICES | 16,700 | -2,91 % | AMN Healthcare Services Inc: AMN Healthcare Announces Third Quarter 2025 Results | Quarterly revenue of $634 million and adjusted EBITDA of $58 million; GAAP income of $0.76/share and adjusted EPS of $0.39 DALLAS, Nov. 06, 2025 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE:... ► Artikel lesen |
ACLARION INC gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell -3,22 % bei einem Aktienkurs von 3,010 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ACLARION INC finden Sie auf Wallstreet Online.